Agents for treating and preventing sleep disorders comprise new and known opioid receptor-like 1 receptor (ORL-1) agonists. Agents for treating and preventing sleep disorders comprise new and known opioid receptor-like 1 receptor agonists. An independent claim is also included for new acenaphthene derivatives of formula (I) and their racemates, enantiomers and salts. [Image] R 1H, A, lower alkyl, lower alkenyl, CO 2H, COA, COOA, COPh, COOA, COOPh, PhCOA, ACOOA, lower alkenyl-COOA, ACONR 3R 4, SO 2A, SO 2Ph, ASA, ASOA, ASO 2A, ASO 2NR 3R 4, Ph or CH 2Ph; A : lower alkyl; Ph : phenyl (optionally substituted by A, halo, OA, phenoxy or benzyloxy); R 2H, A, halo, OA, phenoxy, benzyloxy, CF 3, NO 2, NH 2 or CN; R 3, R 4H, A or lower alkenyl; or NR 3R 4saturated heterocyclyl optionally substituted by A, halo, OA, phenoxy or benzyloxy; and X : O or S. ACTIVITY : CNS-Gen.; Hypnotic. In circadian rhythm sleep tests on rats administration of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,4-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide (Ia) at 3 mg/kg orally advanced the Zeitgeber time by 3 hours compared to a control. MECHANISM OF ACTION : ORL-Agonist.
展开▼
